Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Capricor Therapeutics Inc

CAPR
Current price
13.94 USD -0.25 USD (-1.76%)
Last closed 14.33 USD
ISIN US14070B3096
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 631 122 240 USD
Yield for 12 month +249.37 %
1Y
3Y
5Y
10Y
15Y
CAPR
21.11.2021 - 28.11.2021

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California. Address: 10865 Road to the Cure, San Diego, CA, United States, 92121

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

41.29 USD

P/E ratio

Dividend Yield

Current Year

+25 178 066 USD

Last Year

+2 548 917 USD

Current Quarter

+2 261 642 USD

Last Quarter

+3 971 438 USD

Current Year

+24 109 184 USD

Last Year

+1 854 046 USD

Current Quarter

+2 261 642 USD

Last Quarter

+3 614 503 USD

Key Figures CAPR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -34 769 880 USD
Operating Margin TTM -575.24 %
PE Ratio
Return On Assets TTM -44.49 %
PEG Ratio
Return On Equity TTM -392.69 %
Wall Street Target Price 41.29 USD
Revenue TTM 23 228 044 USD
Book Value 0.73 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -63.40 %
Dividend Yield
Gross Profit TTM 1 746 380 USD
Earnings per share -1.02 USD
Diluted Eps TTM -1.02 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY
Profit Margin -146.86 %

Dividend Analytics CAPR

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History CAPR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:10
Payout Ratio
Last Split Date 05.06.2019
Dividend Date 05.06.2019

Stock Valuation CAPR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 22.37
Price Sales TTM 25.96
Enterprise Value EBITDA -2.73
Price Book MRQ 8.83

Financials CAPR

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CAPR

For 52 weeks

3.52 USD 23.40 USD
50 Day MA 18.47 USD
Shares Short Prior Month 3 845 353
200 Day MA 8.80 USD
Short Ratio 3.90
Shares Short 4 412 443
Short Percent 11.00 %